Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection

Trial Profile

Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
  • Indications Otitis media; Pneumococcal infections; Pneumonia
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 19 Oct 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top